HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
Stocks · News reference
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Wednesday. The Dow traded up 0.40% to 52,432.64 while the NASDAQ declined 0.01% to 25,834.80. The
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
Jensen Huang Says AI Is a 'Five-Layer Cake.' Nvidia Is Just One Slice
Jensen Huang's "five-layer cake" AI framework reveals how companies beyond Nvidia could benefit from the next phase of AI investment.